Physician profile
Andre Rosas
NPI 1669000709
$2,495.63
in general payments reported to CMS, 2019-2025
23 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $369 · 2024: $1,381 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $936.13 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $352.21 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $219.15 | 2024-2025 | |
| Dexcom, INC. | $161.93 | 2023-2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $151.95 | 2025 | Rezdiffra |
| Insulet Corporation | $116.86 | 2024-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $114.00 | 2023-2024 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.66 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $37.33 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $37.17 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $34.35 | 2023-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.52 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $32.30 | 2024-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $31.41 | 2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $26.96 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $26.40 | 2025 | Bd Onclarity |
| Amgen INC. | $26.00 | 2023 | Otezla, Repatha |
| Abbvie INC. | $22.64 | 2024 | |
| Corcept Therapeutics | $19.54 | 2024 | Korlym |
| Inspire Medical Systems, INC. | $16.35 | 2025 | Inspire |
| Ironwood Pharmaceuticals, INC | $15.30 | 2023 | Linzess |
| Novartis Pharmaceuticals Corporation | $13.74 | 2024 | |
| Pfizer INC. | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Rosas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.